SageView Advisory Group’s Spero Therapeutics SPRO Stock Holding History

SageView Advisory Group’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17	Closed	-$40	–	2170
2025 Q4	$40	Buy	+17	New	+$39	﹤0.01%	2572

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SageView Advisory Group's SPRO Position: Q1 2026 in Review

SageView Advisory Group sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 17 shares — an estimated $40 sold.

SageView Advisory Group first reported a position in SPRO in Q4 2025 and held it in 1 quarter. The position peaked at $40 in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

SageView Advisory Group reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 17 Spero Therapeutics shares in Q1 2026, an estimated $40.
SageView Advisory Group first reported a position in Spero Therapeutics in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Spero Therapeutics position peaked at $40 in Q4 2025.
50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.